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To the Editor:
We appreciate Yu and Sun for their comments on our recent ﬁnd-
ings, which focused on the dual functions of interferon (IFN) reg-
ulatory factor 9 (IRF9) on cardiometabolic diseases.
IRF9, also known as IFN-stimulated gene (ISG)F3c or p48,
belongs to the IRF family, which consists of nine members, IRF1-
IRF9, in mammals [1]. Since ﬁrst being identiﬁed in 1990, IRF9
has been shown to be an essential regulator of the innate immune
system and to stimulate the downstream genes of the Janus kinase
(JAK)-signal transducer and activator of transcription (STAT) axis
through its ability to form an ISGF3 complex with STAT1/STAT2
or STAT1/STAT1 [2]. Derived from its important location in the
innate immune network, IRF9 is extensively involved in infectious
conditions and autoimmunediseases [1,2]. Evolutionary reasoning
has indicated that immune response is evolutionarily conserved
and highly integrated into the metabolic system. The interaction
and counterbalance between the immune and the metabolic sys-
tems form a central homeostasis, the dysfunction of which elicits
a series of metabolic disorders, especially insulin resistance and
obesity, as well as cardiovascular diseases [3]. A recent adopted
perspective even presumed that cardiometabolic disease is a
chronic low-grade inﬂammatory response [4]. Considering the
important location of IRF9 in the innate immune network and
the intimate connection between immune response and car-
diometabolic disease, we questioned whether IRF9 can inﬂuence
the pathogenesis of pathological cardiometabolic conditions, and
if so, wewonderedwhether this function depends on immune reg-
ulation by IRF9.
Interestingly, we recently uncovered a dramatic alteration in
IRF9 expression in response to various cardiometabolic stresses,IRF9
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Fig. 1. IRF9 functions as a ‘‘double-edged sword’’ in a series of cardiometabolic diseases. In response to I/R insults and vascular injury, IRF9 directly binds to the
promoter region of Sirt1 to inhibit its expression, which enhances the activations of P53 and AP-1 to exacerbate cell death and VSMC dysfunction, leading to aggravated
tissue damage and neointima formation, respectively. Upon hypertrophic stress, IRF9 competes with P300 for the interaction with Myocardin, and thus blunts
cardiomyocytes enlargement and the resultant cardiac remodelling. During high fat diet-induced metabolic disorder, IRF9 directly binds to PPARa that promotes lypolysis
and reduce lipogenesis, resulting in the blockage of insulin resistance and hepatic steatosis.
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s as novel therapeutic targets for cardiometabolic diseases.
wever, as transcriptional factors, IRFs are difﬁcult to develop
ectly into pharmacological or genetic targets for disease treat-
nt. Instead, upstream factors that determine when, where
how IRFs and their corresponding downstream events are
ivated/suppressed hold greater promise as possible approaches
reating these devastating conditions. Studies focusing on these
ortant issues are in progress in our research group to fully
erstand the potential clinical applications of IRF signalling.
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Letters to the Editor
including ischemia/reperfusion (I/R) stimulation, vascular insult,
hypertrophic stress and high-fat diet, suggesting that IRF9 is a
susceptible cardiometabolic stress sensor that may affect these
pathological conditions. Using genome-wide mRNA arrays and
chromatin immunoprecipitation (ChIP) assays, we consequently
highlighted a putative downstream target of IRF9, Sirt1, the pro-
moter of which provides direct binding sites for IRF9. In response
to I/R, the binding of IRF9 to Sirt1 downregulates Sirt1 transcrip-
tional activity followed by enhanced acetylation and activation of
p53, leading to aggravated cell death and exacerbation of tissue
damage induced by hepatic, cerebral or myocardial I/R [5–7].
Additionally, the IRF9-Sirt1 axis positively regulates activator
protein (AP)-1 reporter activity, which signiﬁcantly promotes
vascular injury-induced neointima formation via enhanced
vasculoproliferative pathology modulation [8]. Accordingly, we
deduced that IRF9, as a classic transcriptional factor, could con-
trol transcriptional activation of downstream genes in response
to cardiometabolic stresses. Another important fact to note is that
IRF9 can act directly on parenchyma cells, not limited to immune
or inﬂammatory cells. The target genes and cells of IRF9 suggest
that, as a critical negative upstream regulator of Sirt1, IRF9 senses
and regulates I/R and vascular insults through immune-indepen-
dent mechanisms.
A deﬁning feature of transcription factors is that they regulate
downstream programmes either through directly binding to tar-
get genes or through protein-protein interactions to regulate the
transcriptional activity of other transcription factors. In addition
to its binding capacity to downstream factor promoters, our sub-
sequent studies demonstrated that IRF9 can inﬂuence the devel-
opment of cardiometabolic diseases through interactions with
other proteins [9,10]. Our research group demonstrated that
IRF9 competes with p300 for the binding domain of myocardin
to disrupt its transcriptional activity and thereby reduces the
hypertrophic response [9]. In diet-induced and genetically
(ob/ob) obese mice, IRF9 directly interacts with peroxisome pro-
liferator-activated receptor a (PPARa) and activates PPARa target
genes, leading to amelioration of dyslipidaemia [10]. Therefore,
as Yu and Sun pointed out, IRF9 is a cardiometabolic stimulus-
response molecule that acts as a ‘‘double-edged sword’’ to
regulate a cluster of cardiometabolic diseases due to their
speciﬁc partners and corresponding molecular events (Fig. 1).
Notably, although IRF9 is an immune regulator, additional
mechanisms that are independent of its immune capacity
have coevolved to regulate cell fate under pathological
cardiometabolic conditions.
The discovery of the cardiometabolic regulation of IRF9
prompts us to ask: ‘What about other IRFs?’ Intriguingly, our
recent studies on IRF1, IRF3, IRF4, IRF7 and IRF8 have
demonstrated that, like IRF9, certain IRFs exhibit stress-speciﬁc
or cell-speciﬁc functions during cardiometabolic diseases through
(but not limited to) an immune-independent manner.
Furthermore, different IRFs exhibit inconsistent or even reverse
phenotypes in certain cardiometabolic diseases, suggesting that
overlapping and/or diverse IRF signallings might exist and form
a complex network [1,2]. Thus, clarifying the crosstalk among dif-
ferent IRFs will offer illuminating glimpses into the applications of
IRF
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